The proto-oncogene c-fgris a member of the c-src gene family of cytoplasmic tyrosine kinases. Previous studies have suggested that it is normally expressed in neutrophils, monocytes, macrophages, and natural killer cells. c-fgr is also expressed in the B cells of certain lymphoproliferative disorders, namely, Epstein-Barr virus-associated lymphoproliferative disease, and in chronic lymphocytic leukemia, but it has not previously been detected in normal or reactive human lymphoid tissue. In this study we have determined the pattern of ~5 5 ' "~' protein expression in normal human hematopoietic and lymphoid tissues at the single-cell level using immunohistochemical and immunofluorescent techniques. We show that ~5 5 " "~~ expression is developmentally The publication costs of this ariicie were defrayed in part by page chnrge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.
regulated with high-level expression first evident at the myelocyte stage of myeloid differentiation. In addition, we show that ~5 5 ' "~' is expressed in circulating B lymphocytes isolated from chronic lymphocytic leukemia patients but is not expressed in normal circulating B lymphocytes. Surprisingly, ~5 5 " '~' is also expressed in a subpopulation of normal B lymphocytes, the mantle zone B lymphocytes. This demonstration that p55** is expressed in a normal B-lymphocyte subpopulation suggests that its expression in certain B e l l lymphoproliferative disorders may be an indirect consequence of, rather than a primary cause of, the neoplastic transformation process.
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bution of p55"'"to the signal transduction pathways of these receptors is unclear. The targeted disruption of ofgr in mice has recently been reported." These mice have normal hematopoeisis. Macrophages isolated from these mice are phenotypically and functionally normal in a variety of in vitro tests. Further, c-fgr mutant mice have an apparently normal immune response to Listeria monocytogenes, an intracellular pathogen. However, mice with targeted disruptions of both c,fgr and hck (but not hck alone) have an increased susceptibility to Listeria monocytogenes. These data indicate that cjgr plays a (as yet undefined) role in the immune response to this pathogen.
The oncogenic potential of the src gene family is well established. v-fgr, v-src, and v-yes were originally identified from acutely transforming retroviruses isolated from naturally occurring
In addition, several of the protooncogenes, including c " , are transforming in NIH 3T3 assays." Finally, the lck protooncogene has been shown to cause thymic tumors in transgenic mice when overexpressed.Ih There has been little data directly linking the csrc gene family with human neoplastic disease. Expression of c-& has been detected in the B cells of chronic lymphocytic leukemia (CLL) patient^'^ and in Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.'"'' Of note, c,fgr expression has not been detected in normal or reactive human lymphoid
The possible disregulation of c y i r in these lymphoproliferative disorders suggests that the c-jkr protooncogene may play an important role in the pathogenesis of these diseases.
This study was designed to carefully examine normal human hematopoietic and lymphoid tissues for c-jgr expression using immunohistochemical techniques to detect ~55'"' at the single-cell level. We show here that c-fgr is developmentally regulated during normal myelomonocytic maturation with high-level ~5 5 " -~~' expression beginning during the myelocyte stage of development. In addition, we show that pSS'"'*'' expression is readily detectable in B cells isolated from patients with CLL but not in normal circulating B lymphocytes. Interestingly, examination of lymphoid tissues demonstrated that p55"iy' is also expressed in a normal B cell subset, the mantle zone B lymphocytes. 
MATERIALS AND METHODS
Production and puriJication of c-fgr antiserum. The region of the human c-fgr gene encoding for amino acids 1 through 88 was subcloned into the prokaryotic expression vector, PET 3a (Novagen, Madison, WI). Recombinant c-fgr peptide was produced in Escherichia coli, as described: ' and the expected 9-kD peptide was purified by electrophoresis through a 12.5% sodium dodecyl sulfate (SDS)-polyacryamide gel. Gel slices containing the isolated c-fgr peptide were used to immunize NZW rabbits. The immunizations, boosts, and phlebotomies were performed by Cocalico Biologicals Inc (Reamstown, PA). A single rabbit was found to have a high titer antibody versus native c-& protein on Western blots (data not shown); this antibody was used in all subsequent studies.
The antiserum was affinity purified over a glutathionine S-transferase (GST)fgr column. The region of the c-fgr gene encoding for amino acids 1 through 247 was subcloned into the prokaryotic expression vector, pGEX-3X (AMRAD, Melbourne, Australia). The resulting GSTfgr chimera was purified on glutathione-conjugated agarose beads (Sigma, St. Louis, MO), as described." The GST:cfgr chimera was covalently linked to the agarose beads by treatment with 0.1% glutaraldehyde (Sigma) for 5 minutes at 4°C. Noncovalently linked fusion protein was eluted from the beads with 0.1 mol/L glycine, pH 2.5. The resulting covalently linked GSTfgr glutathioneagarose complex was used to affinity purify the c-fgr antisera, as described:' after initial purification of the IgG fraction on a protein A column.
Generation of c-fgr-or hck-expressing K562 cell lines. cDNAs for the human c-fgr or hck gene were cloned into the eucaryotic expression vector, Bill-Ne~:~ and transfected by electroporation into K562 cells as previously de~cribed.'~ Neomycin-resistant colonies were isolated after selection in G418 (Gibco BRL, Gaithersburg, MD)-containing media and analyzed by immunoblots to confirm expression of either ~5 5 "~~' or ~5 6~" .
Individual clones that expressed the highest levels of either ~5 5 '~~' or p56" were selected for the immunohistochemical studies. Commercially available hck antiserum (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) was used to confirm ~5 6~'~ expression.
Western blots. Western blots were performed as de~cribed.'~ Anti-pbosphotyrosine antibody (clone 4G10) was purchased from UBI (Lake Placid, NY). The anti-blk antibody was a generous gift of Joseph Bolen (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ). HeLa cell extracts containing the indicated src kinase, a gift of Andrey Shaw (Washington University, St Louis, MO), were prepared using the vaccinia virus-T7 expression system in HeLa cells as described previously:6 except that a 1% NP40 buffer containing 25 mmol/L Tris (pH 7.4), 150 mmoVL NaC1, 1 mmol/L EDTA and 500 U/mL aprotinin (Sigma) was used to lyse the cell pellet. Insoluble material was removed by centrifugation at 10,OOOg for 10 minutes at 4°C.
Immunohistochemistry/immunofiuorescence. Normal peripheral blood and bone marrow aspirate samples were obtained from material submitted to the hematology laboratory of Barnes Hospital, St. Louis, MO. Peripheral blood from patients with CLL was obtained from five consecutive samples submitted to the Washington University Hematology Laboratory, St. Louis, MO. In all cases, contaminating erythrocytes were removed by NKCl lysis:' and the leukocytes were cytospun onto SuperfrostPlus slides (Fisher Scientific, Pittsburgh, PA). The specimens were fixed briefly in ethanol, rehydrated in phosphate-buffered saline (PBS), and blocked in PBS containing 10% goat serum (Sigma). Specimens were then incubated for 4 hours to overnight in a humidified chamber at 4°C with the c-fgr antisera and, where indicated, a murine monoclonal antibody directed against a defined cell surface antigen diluted in 10% goat sera. The murine monoclonal antibodies used in this study have well-defined tissue specificities" and were used at the manufacturers' (DAKO, Carpinteria, CA, for L26, KP-1, and UCHL-l; Clonab, Denville, NJ, for LN-2) recommended dilution: L26 (1:200), KP-1 (1:800), UCHL-1 (1:400), and LN2 (1:20). For the immunohistochemical studies, a biotinylated goat anti-rabbit IgG (Sigma) and alkaline phosphataseconjugated streptavidin complex (Gibco BRL, Gaithersburg, MD) were used for detection. The specimens were developed with alkaline phosphatase substrate kit I1 (Vector Laboratories, Burlingame, CA) and counterstained with methyl green and alacian blue. For the immunofluorescence studies, the specimens were incubated with phycoerythrin-conjugated goat anti-rabbit and fluorescein-conjugated goat anti-mouse F(ab), fragments (TAG0 Immunologicals, Camarillo, CA). Where indicated in the text, the c-fgr antisera was preincubated with a molar excess of either GSTfgr or GST alone for I hour at 4°C.
Lymphoid tissue was obtained from material submitted to the Department of Pathology, Washington University School of Medicine (St. Louis, MO). The tissue was embedded in OCT compound (Miles Laboratories, Elkhart, IN), snap-frozen in liquid-cooled isopentane, and stored at -70°C. The histologic diagnosis was based on conventional hematoxylin-stained, formalin-fixed, paraffin-embedded sections. Frozen sections were cut (6 p), fixed briefly in ethanol, and rehydrated in PBS. Immunostaining studies were performed on these specimens as outlined above.
RESULTS
c-fgr antiserum characterization. The region of the human cygr gene encoding amino acids 1 through 88 was cloned into the prokaryotic expression vector PET 3a, and recombinant c-fsr peptide was isolated as described in Materials and Methods. This peptide was used to immunize rabbits, and the resulting antiserum was affinity purified over a column containing the amino-terminal 247 amino acids of the c-fgr gene fused to the glutathione-S-transferase gene (see Materials and Methods). The specificity of this antiserum was tested with immunoblots and cell staining. HeLa cell extracts containing the indicated src kinase listed in Fig l were blotted in duplicate and probed with either an antiphosphotyrosine antibody (Fig 1A) or the affinity-purified c-fgr antibody (Fig 1B) . Expression of the appropriate sized protein is apparent in each extract, but only p5Y@ is detected with the c-fgr antiserum.
Similar experiments were performed to ensure that the cfgr antiserum did not detect blk protein. Another src-related protein, blk is primarily expressed in B lymphocytes.' Cell extracts were prepared from WEHI-231 cells that express abundant blk but no detectable c-fsr" and from HL60 cells treated with retinoic acid, which express abundant c -f g~.~ These extracts were blotted in duplicate. and hybridized with either anti-blk antiserum (data not shown) or the c-fgr antiserum (Fig 1C) . The p50bik protein is present in the WEHI-231 extract, as expected (data not shown). The c-fgr antiserum readily detects ~5 5 "~~' in the HL60 cell extract but does not crosshybridize with ~506".
The proto-oncogenes hck and cygr have similar patterns of expression.3033' To test the ability of the c-& antiserum to discriminate between p5Ffgr and ~5 6 " '~, K562 cell lines were generated that expressed human c-fgr, human hck, or vector alone. Approximately equivalent amounts of p5Ffgr and ~5 6~" were detected by immunoblotting with the relevant antiserum (data not shown). These cell lines were 
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stained with the c$gr antiserum, as shown in Fig 2. K562 cells expressing ~55'"' stained strongly (Fig 2C) , whereas cell lines expressing vector alone or p56""" (Fig 2A and B,  respectively) showed only background staining. In addition, preincubation of the c-& antiserum with the GST-fgr fusion protein abolished the cellular staining (Fig 2D) . Collectively, these data demonstrate the specificity of this antiserum.
c-fgr expression in hwnan bone marrow cells. Mononuclear cells were purified from normal bone marrow aspirates and stained with the c-fgr antibody. Representative results are shown in Fig 3. The p55"fvr protein was most strongly detected in myelocytes, metamyelocytes, and more mature myeloid cells. Promyelocytes stained less intensely. Cells of erythroid lineage did not stain. The expression of c: & in normal blast cells was difficult to ascertain because of the limited number of identifiable blasts in these cell preparations. These data confirm that c-fgr is predominantly expressed in myelomonocytic cells and suggest that the highest level of expression within the myeloid lineage is seen in terminally differentiated myelornonocytic cells. c-fgr is expressed in a subset of normal R 1ympltocyte.s.
Several recent reports suggested that
is not expressed in normal human B lymphocytes. We used our c-fgr antiserum to examine ~5 5 "~~' expression at the single-cell level in normal B-lymphocyte populations. Frozen sections obtained from normal and reactive lymph node tissues were stained with the c-fgr antiserum; representative results are shown in Fig 4. Moderately intense c-& staining was seen in the mantle zone of the follicle, while the germinal center cells were mostly negative (Fig 4A and C) . Occasional positive cells were also detected in the interfollicular areas. Similar results were obtained with reactive lymph node (data not shown).
To determine the lineage of the cells expressing p5YgR', dual immunofluorescent techniques were used. Frozen sections of normal lymph node tissue were stained with the cfgr antisera and with one of the following antibodies: LN-2 (a B lymphocyte-specific marker that preferentially stains mantle zone B lymphocytes), UCHL-I (a T lymphocytespecific marker), or KP-l (a macrophagehonocyte-specific marker).2x Representative results are shown in Fig 5. LN-2 and c-fgr double-positive cells are seen in the mantle zone, demonstrating that ~55'"' is expressed in mantle zone B lymphocytes. Note that no c-fgr staining is again seen in In contrast to normal circulating B lymphocytes (Fig 6A) , CLL B cells contain readily detectable amounts of ~55""' (Fig 6B) . Note that p5Yqgr is expressed in peripheral blood monocytes, as expected. 
DISCUSSION
Previous studies of c-fgr expression in normal human tissues have used RNA analyses of tissue specimens that contained cells of several different lineage^?.'^.'' Data from these studies suggested that c-fgr was primarily expressed in mature myelomonocytic cells, namely, neutrophils, monocytes, and macrophages. No c-fsr mRNA was detected in normal or reactive lymphoid tissue. In this study we have determined the pattern of expression of ~5 5 "~~~' in hematopoietic and lymphoid tissues at the single-cell level using immunostaining techniques. This approach has enabled us to definitively identify the p55"fg'-expressing cells within a mixed cell population.
In vitro differentiation of murine bone marrow-derived monocytes and myelomonocytic cell lines is associated with an increase in c-fgr expression."6 Furthermore, c-fgr expression in leukemic blasts is associated with a more differentiated myeloid or monocytic phen~type.'.~ Our data demonstrate that p5Yfgr is also induced during normal myeloid differentiation in vivo. High-level ~5 5 '~~' expression is first seen during the myelocyte stage of development and persists through the mature neutrophil stage. The myelocyte stage For personal use only. on January 15, 2018. by guest www.bloodjournal.org From
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LINK AND ZUTTER of myeloid differentiation is notable for the acquisition of secondary granules and for the loss of proliferative capacity as maturation continues to the metamyelocyte stage. It is interesting to speculate that ~55"'~' may play a role in the terminal differentiation of neutrophils. A similar function has been postulated for ~5 6 "~ during T-cell development.'* As noted above, previous studies have detected little or no c-fgr expression in human lymphoid tissues. In the current study, we have detected moderate ~55"~8' levels in mantle zone B lymphocytes. In contrast, no ~55'"~' was detected in germinal center or peripheral blood B lymphocytes. The observed difference in p5Yf*' expression between the current study and previous studies is most likely secondary to the ability of immunostaining techniques to detect pSSc-fy' in a minor cell type within an otherwise negative mixed cell population. In agreement with our data, Hatakeyama et al"' recently reported that pSSc"8r is expressed at high levels in murine lymph node, although the identification of ~5 5 "~~' -expressing cells within the lymph node was not performed in this study.
Mantle zone B lymphocytes are small resting B lymphocytes3' In contrast to germinal center B lymphocytes, mantle zone B lymphocytes are capable of secreting immunoglobulin in response to pokeweed mitogen." Phenotypically, mantle zone B lymphocytes most closely resemble peripheral blood B lymphocytes, with surface expression of IgM, IgD, CD20, CD21, and Leu-S antigen^.^^.^' The precise role that mantle zone B lymphocytes play in the immune response, as well as the biologic significance of p5S'",q' expression in these cells, is not currently known. Expression of several other members of the c-src gene family has been detected in B lymphocytes, including pS6'"', p53/56'"', pS9'"', and ~5 0 " '~. ' In particular, p.56"" expression has been detected in the dense lymphocyte fraction obtained from gradient centrifugation of tonsillar lymphocyte^:^^ this fraction is known to contain the mantle zone lymphocytes." Several members of the src gene family have been implicated in the signal transduction pathway of the IgM receptor comp l e~. ' '~~~ It may be that cTfgr serves a similar function for a B-lymphocyte receptor that functions in this restricted Blymphocyte subpopulation. It would be interesting to examine mice with the targeted disruption of the c-fgr gene for abnormalities in their humoral immune response.
A consistent finding in EBV-infected B-cell lines and EBV-immortalized B-lymphoblastoid lines is the expression of c-fgr mRNA and protein at levels comparable with that seen in normal monocytes or n e~t r o p h i l s . '~.~~ W e have shown that c-fsr transcripts in EBV-positive B cells arise from a promoter that is distinct from that used in myelomonocytic
The contribution of EBV to the regulation of c-fgr expression in B cells is controversial. Sharp et aI4' reported that the EBV-negative B-cell line Rarnos had higher c-fgr mRNA levels than several EBV-positive B-cell lines. In addition, they demonstrated that c-fsr expression was downregulated in EBV-positive B-cell lines with a-interferon treatment. Their data suggested that c-fgr expression was not directly regulated by EBV. In contrast, Knutson4' reported that acute infection of primary B lymphocytes or EBV-negative B-cell lines with EBV was associated with an increase in cTfgr mRNA levels. Furthermore, she reported that the EBNA-2 gene of EBV was sufficient to upregulate cTfgr expression in an EBV-negative B-cell line. Our laboratory has been unable to reproduce these results; we have found no consistent elevation of c-fgr mRNA levels with either acute EBV infection or EBNA-2 expression in B cells (Link DC, Sugden B, and Ley TJ, unpublished observations, May 1991). In the current study, we demonstrate that pS5'~fRr is expressed in a normal B-lymphocyte subset. This observation suggests that c7fgr expression in B cells is regulated by a specific B-cell genetic program. Collectively, these data suggest that c-fgr expression is indirectly regulated by EBV; EBV may, under certain circumstances, trigger a specific Bcell program that leads to c-fgr expression.
Abts et all7 reported a survey of c-fgr expression in various lymphoid malignancies. They found that all 22 of the CLLderived samples had readily detectable c-fgr mRNA, whereas normal circulating B lymphocytes had no detectable cTfgr mRNA. This study did not, however, exclude contaminating monocytes from the CLL B-cell preparations: these monocytes may have contributed significantly to the c j k r mRNA detected in these preparations. To avoid this problem, we examined ~55'""' expression in CLL B cells at the singlecell level. Our findings show that, indeed, ~5 5 "~" " is expressed in the circulating B cells of patients with CLL. Further, we have detected ~55'""'' expression in tumor specimens of patients with well-differentiated lymphocytic lymphoma, a B-cell disorder closely related to CLL (Link and Zutter. unpublished observations, January 1994).
The pathogenesis of CLL at a molecular level is poorly understood. Evidence for the disregulation of the c-fsr protooncogene in these B cells might suggest an important role for cTfgr in the pathogenesis of CLL. However, the demonstration that c-fgr is expressed in a normal B-lymphocyte subpopulation suggests that its expression in this lymphoproliferative disorder may result from the activation of a specific B-cell genetic program. Its expression in these neoplastic B cells may, therefore, be an indirect consequence of, rather than a primary cause of, the neoplastic transformation process.
